Biotech News

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) And 2025 Form 20-f Annual Report

Innate Pharma (IPHA)Innate Pharma2026-04-02 07:09 ESTCompany update

Innate Pharma Publie Son Document D’enregistrement Universel 2025 Et Son Rapport Annuel « Form 20-f » 2025

jeu, 04/02/2026 - 10:00

Press release in English 124.91 Ko Communiqué de presse en français 129.86 Ko

helene

jeu, 04/02/2026 - 09:23

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

IPHAInnate Pharma2026-08-09 20:37 EST

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

Stock data

Close: 2.26 USD
Market cap: 170.9M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) And 2025 Form 20-f Annual Report

Related news

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

Innate Pharma announces conference call and webcast

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors